Boothbay Fund Management’s Axsome Therapeutics AXSM Stock Holding History

Boothbay Fund Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-36,900	Closed	-$2.65M	–	1726
2023 Q2	$2.65M	Buy	36,900 +5,600	+18%	+$413K	0.06%	445
2023 Q1	$1.93M	Sell	31,300 -109,600	-78%	-$7.2M	0.04%	683
2022 Q4	$10.9M	Sell	140,900 -1,000	-0.7%	-$59.8K	0.25%	57
2022 Q3	$6.33M	Sell	141,900 -141,100	-50%	-$7.05M	0.16%	121
2022 Q2	$10.8M	Sell	283,000 -86,600	-23%	-$2.74M	0.29%	43
2022 Q1	$15.3M	Buy	369,600 +208,300	+129%	+$6.46M	0.36%	31
2021 Q4	$6.09M	Buy	161,300 +56,800	+54%	+$2.09M	0.14%	160
2021 Q3	$3.44M	Buy	+104,500	New	+$4.07M	0.1%	257
2020 Q2	–	Sell	-113	Closed	-$665K	–	966
2020 Q1	$665K	Buy	113 +68	+151%	+$5.54K	0.06%	399
2019 Q4	$465K	Buy	+45	New	+$1.82K	0.04%	507

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Boothbay Fund Management's AXSM Position: Q2 2026 in Review

Boothbay Fund Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 6,436 shares worth $1.58M. The stake represents 0.02% of the portfolio and ranks #848 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in AXSM as recently as Q2 2025.

Boothbay Fund Management first reported a position in AXSM in Q4 2021 and has held it in 3 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Boothbay Fund Management held 6,436 shares of Axsome Therapeutics worth $1.58M as of Q2 2026.
Axsome Therapeutics was a new Boothbay Fund Management position in Q2 2026.
Axsome Therapeutics made up 0.02% of Boothbay Fund Management's portfolio in Q2 2026, its #848 holding.
Boothbay Fund Management first reported a position in Axsome Therapeutics in Q4 2021 and has held it in 3 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.